A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX - ISTH Congress Abstracts
A multiple ascending dose study of Mim8 in patients with severe haemophilia A with or without factor VIII inhibitors
Pharmaceuticals | Free Full-Text | Updates on Novel Non-Replacement Drugs for Hemophilia
%20for%20Hemophilia.png?md=1 "NNC0365-3769 (Mim8) for Hemophilia Clinical Trial 2023 | Power")
NNC0365-3769 (Mim8) for Hemophilia Clinical Trial 2023 | Power
Summer 2022 haemophilia trial update - European Pharmaceutical Review
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors - ISTH Congress Abstracts
Marianne Kjalke's research works | Novo Nordisk, Copenhagen and other places
Novo Nordisk to buyout Emisphere Technologies for $1.8B (NYSE:NVO) | Seeking Alpha
Study Set to Assess Mim8 Therapy in People With Hemophilia A
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
Mim8 clinical development program: an overview of the FRONTIER studies
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Novo Nordisk outlines strategy for revamped rare diseases unit | BioWorld
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood - ISTH Congress Abstracts
Novo makes a rare disease push | Evaluate
A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys - Lauritzen - 2022 - Journal of Thrombosis and
Mim8 Well-tolerated in Early Study, Paving Way for Phase 3 Hem A Trials | Hemophilia A Clinical Trials for Mim8 Supported by Early Results | Hemophilia News Today
Novo Nordisk's hemophilia drug shows potential as once-monthly treatment — MedWatch
